RxDoctor Payments Data

Mark Lee, MD

Clinical Cardiac Electrophysiology · Long Beach, CANPI 1487943510

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $85,976 of the $126,794 with a category attached, or 67.8%. 57 manufacturers reported payments, led by Biosense Webster, Inc. at 55.4% of the total.

$126,794in general payments, 2019–2025

Across 880 payments — averaging $144.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$70K
  • Medical Device Business Services, Inc.$17K
  • Abbott$10K
  • Medtronic$9K
  • Wilson Cook Medical Incorporated$4K
  • Boston Scientific$3K
  • plus $14K from 51 others
$72,859in research payments, 2019–2025

Across 4 payments — averaging $18,215 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$73K

What the payments were for

  • Consulting fees$85,97668%
  • Speaking & faculty fees$5,7755%
  • Travel & lodging$12,93410%
  • Food & beverage$21,90017%
  • Education$2090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biosense Webster, Inc.90$70,280
Medical Device Business Services, Inc.19$16,829
Abbott51$9,958
Medtronic(2 entities)134$9,109
Wilson Cook Medical Incorporated2$3,600
Boston Scientific78$2,722
Johnson & Johnson75$1,473
Atricure, Inc.13$1,380
Novartis75$1,377
Cook Incorporated4$914
Eli Lilly10$913
Pfizer43$835
Sanofi-aventis U.S. LLC34$767
AstraZeneca29$622
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)27$604
E.r. Squibb & Sons, L.L.C.32$531
Amgen24$507
Inari Medical, Inc.1$375
Boehringer Ingelheim13$342
Cardiva Medical, Inc.14$341
Merck15$322
Kestra Medical Technology Services, Inc.9$320
Astellas Pharma US Inc2$198
Impulse Dynamics (USA) Inc.6$196
Philips North America LLC5$193
Actelion Pharmaceuticals US, Inc.7$154
Kiniksa Pharmaceuticals, Ltd.6$144
Regeneron Healthcare Solutions, Inc.7$140
Altathera Pharmaceuticals LLC2$136
W. L. Gore & Associates, Inc.6$131
Biotronik Inc.3$125
Stryker1$111
Esperion Therapeutics, Inc.4$93
Amarin Pharma, Inc.4$90
Abiomed2$90
Cook Medical LLC3$89
Acutus Medical, Inc.1$73
Lantheus Medical Imaging, Inc.3$70
Heartflow, Inc.3$66
Merz North America, Inc.1$56
Lexicon Pharmaceuticals, Inc.2$55
Arbor Pharmaceuticals, Inc.3$50
Bayer2$43
Cardiofocus, Inc.1$36
Corindus Inc.1$36
Novo Nordisk2$36
Kiniksa Pharmaceuticals International, PLC1$32
Baxter Healthcare1$30
Inspire Medical Systems, Inc.1$28
Alnylam Pharmaceuticals Inc.1$28
Irhythm Technologies, Inc.1$23
Cvrx, Inc.1$23
Biom'up France SAS1$22
Scpharmaceuticals Inc.1$22
Smith+Nephew1$19
Kowa Pharmaceuticals America, Inc.1$18
Bardy Diagnostics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,794 in reported general payments places this provider in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$668,274
Medicare patients
650
Services billed
4,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$345,334
XareltoRivaroxaban41$61,102
EntrestoSacubitril/Valsartan37$47,201
BrilintaTicagrelor17$11,066
Dabigatran EtexilateDabigatran Etexilate Mesylate23$4,918
Metoprolol Succinate177$3,291
Amiodarone Hcl69$2,442
Flecainide Acetate60$2,293
Nebivolol Hcl29$1,516
Dofetilide17$1,449
Atorvastatin Calcium79$1,199
Rosuvastatin Calcium53$894
Losartan Potassium46$772
ClopidogrelClopidogrel Bisulfate50$706
Metoprolol Tartrate44$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$835$345,334280 claims
Johnson & JohnsonXarelto$1,473$61,10241 claims
NovartisEntresto$1,377$47,20137 claims
AstraZenecaBrilinta$622$11,06617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →